Epigenetics Drugs and Diagnostic Technologies Market is expected to grow at a CAGR of 19% during the forecast period. Global Epigenetics Drugs and Diagnostic Technologies Market is expected to reach US$ 45.9 Bn. by 2029.Epigenetics Drugs and Diagnostic Technologies Market Overview
Epigenetics can be termed as the research of chemical remodelling’s of any genes of an organism. A gene can be modified with a variation in the order of its epigenetic programming or DNA. Epigenetic drugs make it possible to transform the particular gene expression, which leads to various disease categories. The increasing prevalence of cancer is anticipated to propel the global epigenetics drugs and diagnostic technologies market over the forecast period. Funding for research and development in epigenetics is anticipated to provide favourable growth opportunities for businesses in the global epigenetics drugs and diagnostic technologies market.To know about the Research Methodology :- Request Free Sample Report Increased prevalence of cancer and other chronic conditions, along with the growing geriatric population, are some of the principal factors anticipated to drive the market. Organizations, such as the National Cancer Institute (NCI), the International Human Epigenome Consortium (IHEC), and the National Institute of Health (NIH), provide funding and aid to research and development exercises in the field of epigenetics. Increasing demands to understand epigenetic alterations at the molecular level and develop remedial solutions are expected to motivate the organizations to fund research and development programs are fuelling the market growth. Also, attempts such as the Epidemiology and Genomics Research Program (EGRP) in the NCI's Division of Cancer grants research initiatives due to new epigenetic research that helps in driving the market growth. Longer durations of research and development for producing epigenetic drugs are expected to hinder the growth of the market. Further, a shortage of data regarding the effectiveness of epigenetic therapy in solid tumours is also expected to limit market growth. The report contains detailed analysis of Strengths, Weakness and opportunities of the key players operating in the Epigenetics Drugs and Diagnostic Technologies Market. It also provides information on current market trends, competitive ranking analysis, regional bifurcation, turnover forecasts, industry drivers and the key challenges. The report has profiled more than fifteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analysing the market and estimation the size of the same. The growing healthcare infrastructure in each region is different and focus is given on availability of advanced technology and new techniques.
Epigenetics Drugs and Diagnostic Technologies Market Segment Analysis
By product type, the kits product segment is the fastest-growing segment over the forecast period. Many biotechnology businesses produce ready-to-use kits for the exposure of epigenetic alterations. Kits available in the market are range from kits for analysis of DNA methylation status, nucleic acid purification, and detection of histone modifications by various enzymes to kits for chromatin immunoprecipitation. Epigenetic diagnostic kits are utilized to diagnose disorders due to epigenetic alterations in the early stages and during treatment to check the effectiveness of therapeutics. They work based on immunoprecipitation by the association of modification-specific monoclonal antibodies. By technology, the Global market is segmented into- chromatin structures, micro RNA modification, large non-coding RNA, histone acetylation, histone methylation and DNA methylation. Histone Acetylation is anticipated to show the fastest growth over the forecast period. Its enhanced effectiveness owing to the initiation of new mechanisms can be attributed to the growth. Histone acetylation controls cellular processes, such as chromatin transcription, gene silencing, and dynamics, differentiation, apoptosis, DNA replication, the progression of the cell cycle, nuclear import, neuronal repression, and DNA repair. North America accounted for the largest share of xx% in 2020, reason being the rising prevalence of cancer and also the rising geriatric population. Growth in insurance coverage in the U.S. has increased the burden on the country’s healthcare system, which has highlighted the need for improving efficiency and management of work in North America. Well-established healthcare infrastructure, ease of availability is also a key driver affecting the market growth. Investments by key players in this field has boosted the market growth. Rising adoption of technologically advanced diagnostic imaging systems for lymphedema is rapidly growing the market. Asia Pacific is also expected to witness significant growth during the forecast period due to the increasing geriatric population and rising health care expenditures. The allocation of a large amount of healthcare expenditure for hospitals and dispensing medicines to the elderly is expected drive the market demand. The report also helps in understanding Global Epigenetics Drugs and Diagnostic Technologies Market dynamics, structure by analysing the market segments and project the Global market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global market make the report investor’s guide.Epigenetics Drugs and Diagnostic Technologies Market Scope: Inquire before Buying
Global Epigenetics Drugs and Diagnostic Technologies Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 13.58 Bn. Forecast Period 2023 to 2029 CAGR: 19% Market Size in 2029: US $ 45.9 Bn. Segments Covered: by Product Reagents Kits ChIP Sequencing Kit Whole Genomic Amplification Kit Bisulfite Conversion Kit RNA Sequencing Kit Others Instruments Enzymes Services by Technology DNA Methylation Histone Methylation Histone Acetylation Large Non-coding RNA MicroRNA Modification Chromatin Structures by Type of Therapy Histone Deacetylase (HDAC) Inhibitors DNA Methyltransferase (DNMT) Inhibitors by Applications Oncology Solid Tumors Liquid Tumors Non-oncology Inflammatory Diseases Metabolic Diseases Infectious Diseases Cardiovascular Diseases Others Epigenetics Drugs and Diagnostic Technologies Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Epigenetics Drugs and Diagnostic Technologies Market Key Players
1.Acetylon Pharmaceuticals INC 2.Cell Centric LTD 3.Celgene Corporation 4.Epigentek Group, INC 5.Envivo Pharmaceuticals, INC 6.Oryzon Genomics 7.S.A. 8.4SC AG 9.Celleron Therapeutics 10.Eisai Co. LTD 11.Astex Pharmaceuticals 12.Base Genomics 13.Chroma Therapeutics 14.Roche Diagnostics 15.Thermo Fisher Scientific 16.Novartis AG 17.Illumina INC 18.Qiagen 19.Abcam PLC 20.Merck KGaA Frequently Asked Questions: 1. Which region has the largest share in Global Epigenetics Drugs and Diagnostic Technologies Market? Ans: North America region held the highest share in 2022. 2. What is the growth rate of Global Epigenetics Drugs and Diagnostic Technologies Market? Ans: The Global market is growing at a CAGR of 19% during forecasting period 2023-2029. 3. What is scope of the Global Epigenetics Drugs and Diagnostic Technologies market report? Ans: Global market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Epigenetics Drugs and Diagnostic Technologies market? Ans: The important key players in the Global market are – Celgene Corporation, Epigentek Group, INC, Envivo Pharmaceuticals, INC, Oryzon Genomics, S.A., 4SC AG, Celleron Therapeutics, Eisai Co. LTD, Astex Pharmaceuticals, Base Genomics, Chroma Therapeutics, Roche Diagnostics, Thermo Fisher Scientific, Novartis AG, Illumina INC, Qiagen, Abcam PLC, and Merck KGaA 5. What is the study period of this market? Ans: The Global market is studied from 2022 to 2029.
Global Epigenetics Drugs and Diagnostic Technologies Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Size, By Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Analysis and Forecast 6.1. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Analysis and Forecast, By Product 7.1. Introduction and Definition 7.2. Key Findings 7.3. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Product 7.4. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Size (US$ Mn) Forecast, By Product 7.5. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Analysis, By Product 7.6. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Attractiveness Analysis, By Product 8. Global EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Analysis and Forecast, By Technology 8.1. Introduction and Definition 8.2. Key Findings 8.3. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Technology 8.4. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Size (US$ Mn) Forecast, By Technology 8.5. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Analysis, By Technology 8.6. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Attractiveness Analysis, By Technology 9. Global EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Analysis and Forecast By Type of Therapy 9.1. Introduction and Definition 9.2. Key Findings 9.3. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Type of Therapy 9.4. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Size (US$ Mn) Forecast, By Type of Therapy 9.5. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Analysis, By Type of Therapy 9.6. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Attractiveness Analysis, By Type of Therapy 10. Global EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Analysis and Forecast By Applications 10.1. Introduction and Definition 10.2. Key Findings 10.3. EPIGENETICS DRUGS AND TECHNOLOGIES Market Value Share Analysis, By Applications 10.4. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Size (US$ Mn) Forecast, By Applications 10.5. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Analysis, By Applications 10.6. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Attractiveness Analysis, By Applications 11. Global EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Analysis, By Region 11.1. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOIES Market Value Share Analysis, By Region 11.2. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Size (US$ Mn) Forecast, By Region 11.3. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Attractiveness Analysis, By Region 12. North America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Analysis 12.1. Key Findings 12.2. North America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Overview 12.3. North America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Product 12.4. North America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 12.4.1. Reagents 12.4.2. Kits 12.4.3. Instruments 12.4.4. Enzymes 12.4.5. Services 12.5. North America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Technology 12.6. North America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 12.6.1. DNA Methylation 12.6.2. Histone Methylation 12.6.3. Histone Acetylation 12.6.4. Large Non-coding RNA 12.6.5. MicroRNA Modification 12.6.6. Chromatin Structures 12.7. North America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Type of Therapy 12.8. North America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 12.8.1. Histone Deacetylase (HDAC) Inhibitors 12.8.2. DNA Methyltransferase (DNMT) Inhibitors 12.9. North America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Applications 12.10. North America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 12.10.1. Oncology 12.10.2. Non-oncology 12.11. North America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Country 12.12. North America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Country 12.12.1. U.S. 12.12.2. Canada 12.12.3. Mexico 12.13. North America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Analysis, By Country 12.14. U.S. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 12.14.1. Reagents 12.14.2. Kits 12.14.3. Instruments 12.14.4. Enzymes 12.14.5. Services 12.15. U.S. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 12.15.1. DNA Methylation 12.15.2. Histone Methylation 12.15.3. Histone Acetylation 12.15.4. Large Non-coding RNA 12.15.5. MicroRNA Modification 12.15.6. Chromatin Structures 12.16. U.S. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 12.16.1. Histone Deacetylase (HDAC) Inhibitors 12.16.2. DNA Methyltransferase (DNMT) Inhibitors 12.17. U.S. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 12.17.1. Oncology 12.17.2. Non-oncology 12.18. Canada EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 12.18.1. Reagents 12.18.2. Kits 12.18.3. Instruments 12.18.4. Enzymes 12.18.5. Services 12.19. Canada EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 12.19.1. DNA Methylation 12.19.2. Histone Methylation 12.19.3. Histone Acetylation 12.19.4. Large Non-coding RNA 12.19.5. MicroRNA Modification 12.19.6. Chromatin Structures 12.20. Canada EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 12.20.1. Histone Deacetylase (HDAC) Inhibitors 12.20.2. DNA Methyltransferase (DNMT) Inhibitors 12.21. Canada EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 12.21.1. Oncology 12.21.2. Non-oncology 12.22. Mexico EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 12.22.1. Reagents 12.22.2. Kits 12.22.3. Instruments 12.22.4. Enzymes 12.22.5. Services 12.23. Mexico EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 12.23.1. DNA Methylation 12.23.2. Histone Methylation 12.23.3. Histone Acetylation 12.23.4. Large Non-coding RNA 12.23.5. MicroRNA Modification 12.23.6. Chromatin Structures 12.24. Mexico EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 12.24.1. Histone Deacetylase (HDAC) Inhibitors 12.24.2. DNA Methyltransferase (DNMT) Inhibitors 12.25. Mexico EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 12.25.1. Oncology 12.25.2. Non-oncology 12.26. North America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Attractiveness Analysis 12.26.1. By Product 12.26.2. By Technology 12.26.3. By Type of Therapy 12.26.4. By Applications 12.27. PEST Analysis 12.28. Key Trends 12.29. Key Developments 13. Europe EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Analysis 13.1. Key Findings 13.2. Europe EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Overview 13.3. Europe EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Product 13.4. Europe EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 13.4.1. Reagents 13.4.2. Kits 13.4.3. Instruments 13.4.4. Enzymes 13.4.5. Services 13.5. Europe EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Technology 13.6. Europe EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 13.6.1. DNA Methylation 13.6.2. Histone Methylation 13.6.3. Histone Acetylation 13.6.4. Large Non-coding RNA 13.6.5. MicroRNA Modification 13.6.6. Chromatin Structures 13.7. Europe EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Type of Therapy 13.8. Europe EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 13.8.1. Histone Deacetylase (HDAC) Inhibitors 13.8.2. DNA Methyltransferase (DNMT) Inhibitors 13.9. Europe EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Applications 13.10. Europe EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 13.10.1. Oncology 13.10.2. Non-oncology 13.11. Europe EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Country 13.12. Europe EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Country 13.12.1. Germany 13.12.2. U.K. 13.12.3. France 13.12.4. Italy 13.12.5. Spain 13.12.6. Sweden 13.12.7. CIS countries 13.12.8. Rest of Europe 13.13. Germany EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 13.13.1. Reagents 13.13.2. Kits 13.13.3. Instruments 13.13.4. Enzymes 13.13.5. Services 13.14. Germany EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 13.14.1. DNA Methylation 13.14.2. Histone Methylation 13.14.3. Histone Acetylation 13.14.4. Large Non-coding RNA 13.14.5. MicroRNA Modification 13.14.6. Chromatin Structures 13.15. Germany EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 13.15.1. Histone Deacetylase (HDAC) Inhibitors 13.15.2. DNA Methyltransferase (DNMT) Inhibitors 13.16. Germany EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 13.16.1. Oncology 13.16.2. Non-oncology 13.17. U.K. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 13.17.1. Reagents 13.17.2. Kits 13.17.3. Instruments 13.17.4. Enzymes 13.17.5. Services 13.18. U.K. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 13.18.1. DNA Methylation 13.18.2. Histone Methylation 13.18.3. Histone Acetylation 13.18.4. Large Non-coding RNA 13.18.5. MicroRNA Modification 13.18.6. Chromatin Structures 13.19. U.K. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 13.19.1. Histone Deacetylase (HDAC) Inhibitors 13.19.2. DNA Methyltransferase (DNMT) Inhibitors 13.20. U.K. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 13.20.1. Oncology 13.20.2. Non-oncology 13.21. France EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 13.21.1. Reagents 13.21.2. Kits 13.21.3. Instruments 13.21.4. Enzymes 13.21.5. Services 13.22. France EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 13.22.1. DNA Methylation 13.22.2. Histone Methylation 13.22.3. Histone Acetylation 13.22.4. Large Non-coding RNA 13.22.5. MicroRNA Modification 13.22.6. Chromatin Structures 13.23. France EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 13.23.1. Histone Deacetylase (HDAC) Inhibitors 13.23.2. DNA Methyltransferase (DNMT) Inhibitors 13.24. France EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 13.24.1. Oncology 13.24.2. Non-oncology 13.25. Italy EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 13.25.1. Reagents 13.25.2. Kits 13.25.3. Instruments 13.25.4. Enzymes 13.25.5. Services 13.26. Italy EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 13.26.1. DNA Methylation 13.26.2. Histone Methylation 13.26.3. Histone Acetylation 13.26.4. Large Non-coding RNA 13.26.5. MicroRNA Modification 13.26.6. Chromatin Structures 13.27. Italy EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 13.27.1. Histone Deacetylase (HDAC) Inhibitors 13.27.2. DNA Methyltransferase (DNMT) Inhibitors 13.28. Italy EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 13.28.1. Oncology 13.28.2. Non-oncology 13.29. Spain EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 13.29.1. Reagents 13.29.2. Kits 13.29.3. Instruments 13.29.4. Enzymes 13.29.5. Services 13.30. Spain EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 13.30.1. DNA Methylation 13.30.2. Histone Methylation 13.30.3. Histone Acetylation 13.30.4. Large Non-coding RNA 13.30.5. MicroRNA Modification 13.30.6. Chromatin Structures 13.31. Spain EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 13.31.1. Histone Deacetylase (HDAC) Inhibitors 13.31.2. DNA Methyltransferase (DNMT) Inhibitors 13.32. Spain EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 13.32.1. Oncology 13.32.2. Non-oncology 13.33. Sweden EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 13.33.1. Reagents 13.33.2. Kits 13.33.3. Instruments 13.33.4. Enzymes 13.33.5. Services 13.34. Sweden EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 13.34.1. DNA Methylation 13.34.2. Histone Methylation 13.34.3. Histone Acetylation 13.34.4. Large Non-coding RNA 13.34.5. MicroRNA Modification 13.34.6. Chromatin Structures 13.35. Sweden EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 13.35.1. Histone Deacetylase (HDAC) Inhibitors 13.35.2. DNA Methyltransferase (DNMT) Inhibitors 13.36. Sweden EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 13.36.1. Oncology 13.36.2. Non-oncology 13.37. CIS countries EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 13.37.1. Reagents 13.37.2. Kits 13.37.3. Instruments 13.37.4. Enzymes 13.37.5. Services 13.38. CIS countries EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 13.38.1. DNA Methylation 13.38.2. Histone Methylation 13.38.3. Histone Acetylation 13.38.4. Large Non-coding RNA 13.38.5. MicroRNA Modification 13.38.6. Chromatin Structures 13.39. CIS countries EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 13.39.1. Histone Deacetylase (HDAC) Inhibitors 13.39.2. DNA Methyltransferase (DNMT) Inhibitors 13.40. CIS countries EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 13.40.1. Oncology 13.40.2. Non-oncology 13.41. Rest of Europe EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 13.41.1. Reagents 13.41.2. Kits 13.41.3. Instruments 13.41.4. Enzymes 13.41.5. Services 13.42. Rest of Europe EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 13.42.1. DNA Methylation 13.42.2. Histone Methylation 13.42.3. Histone Acetylation 13.42.4. Large Non-coding RNA 13.42.5. MicroRNA Modification 13.42.6. Chromatin Structures 13.43. Rest of Europe EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 13.43.1. Histone Deacetylase (HDAC) Inhibitors 13.43.2. DNA Methyltransferase (DNMT) Inhibitors 13.44. Rest of Europe EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 13.44.1. Oncology 13.44.2. Non-oncology 13.45. Europe EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Attractiveness Analysis 13.45.1. By Technology 13.45.2. By Product 13.45.3. By Type of Therapy 13.45.4. By Applications 13.46. PEST Analysis 13.47. Key Trends 13.48. Key Developments 14. Asia Pacific EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Analysis 14.1. Key Findings 14.2. Asia Pacific EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Overview 14.3. Asia Pacific EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Product 14.4. Asia Pacific EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 14.4.1. Reagents 14.4.2. Kits 14.4.3. Instruments 14.4.4. Enzymes 14.4.5. Services 14.5. Asia Pacific EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Technology 14.6. Asia Pacific EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 14.6.1. DNA Methylation 14.6.2. Histone Methylation 14.6.3. Histone Acetylation 14.6.4. Large Non-coding RNA 14.6.5. MicroRNA Modification 14.6.6. Chromatin Structures 14.7. Asia Pacific EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Type of Therapy 14.8. Asia Pacific EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 14.8.1. Histone Deacetylase (HDAC) Inhibitors 14.8.2. DNA Methyltransferase (DNMT) Inhibitors 14.9. Asia Pacific EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Applications 14.10. Asia Pacific EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 14.10.1. Oncology 14.10.2. Non-oncology 14.11. Asia Pacific EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Country 14.12. Asia Pacific EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Country 14.12.1. China 14.12.2. India 14.12.3. Japan 14.12.4. South Korea 14.12.5. Australia 14.12.6. ASEAN 14.12.7. Rest of Asia Pacific 14.13. Asia Pacific EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Analysis, By Country 14.14. China EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 14.14.1. Reagents 14.14.2. Kits 14.14.3. Instruments 14.14.4. Enzymes 14.14.5. Services 14.15. China EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 14.15.1. DNA Methylation 14.15.2. Histone Methylation 14.15.3. Histone Acetylation 14.15.4. Large Non-coding RNA 14.15.5. MicroRNA Modification 14.15.6. Chromatin Structures 14.16. China EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 14.16.1. Histone Deacetylase (HDAC) Inhibitors 14.16.2. DNA Methyltransferase (DNMT) Inhibitors 14.17. China EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 14.17.1. Oncology 14.17.2. Non-oncology 14.18. India EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 14.18.1. Reagents 14.18.2. Kits 14.18.3. Instruments 14.18.4. Enzymes 14.18.5. Services 14.19. India EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 14.19.1. DNA Methylation 14.19.2. Histone Methylation 14.19.3. Histone Acetylation 14.19.4. Large Non-coding RNA 14.19.5. MicroRNA Modification 14.19.6. Chromatin Structures 14.20. India EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 14.20.1. Histone Deacetylase (HDAC) Inhibitors 14.20.2. DNA Methyltransferase (DNMT) Inhibitors 14.21. India EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 14.21.1. Oncology 14.21.2. Non-oncology 14.22. Japan EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 14.22.1. Reagents 14.22.2. Kits 14.22.3. Instruments 14.22.4. Enzymes 14.22.5. Services 14.23. Japan EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 14.23.1. DNA Methylation 14.23.2. Histone Methylation 14.23.3. Histone Acetylation 14.23.4. Large Non-coding RNA 14.23.5. MicroRNA Modification 14.23.6. Chromatin Structures 14.24. Japan EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 14.24.1. Histone Deacetylase (HDAC) Inhibitors 14.24.2. DNA Methyltransferase (DNMT) Inhibitors 14.25. Japan EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 14.25.1. Oncology 14.25.2. Non-oncology 14.26. South Korea EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 14.26.1. Reagents 14.26.2. Kits 14.26.3. Instruments 14.26.4. Enzymes 14.26.5. Services 14.27. South Korea EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 14.27.1. DNA Methylation 14.27.2. Histone Methylation 14.27.3. Histone Acetylation 14.27.4. Large Non-coding RNA 14.27.5. MicroRNA Modification 14.27.6. Chromatin Structures 14.28. South Korea EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 14.28.1. Histone Deacetylase (HDAC) Inhibitors 14.28.2. DNA Methyltransferase (DNMT) Inhibitors 14.29. South Korea EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 14.29.1. Oncology 14.29.2. Non-oncology 14.30. Australia EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 14.30.1. Reagents 14.30.2. Kits 14.30.3. Instruments 14.30.4. Enzymes 14.30.5. Services 14.31. Australia EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 14.31.1. DNA Methylation 14.31.2. Histone Methylation 14.31.3. Histone Acetylation 14.31.4. Large Non-coding RNA 14.31.5. MicroRNA Modification 14.31.6. Chromatin Structures 14.32. Australia EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 14.32.1. Histone Deacetylase (HDAC) Inhibitors 14.32.2. DNA Methyltransferase (DNMT) Inhibitors 14.33. Australia EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 14.33.1. Oncology 14.33.2. Non-oncology 14.34. ASEAN EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 14.34.1. Reagents 14.34.2. Kits 14.34.3. Instruments 14.34.4. Enzymes 14.34.5. Services 14.35. ASEAN EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 14.35.1. DNA Methylation 14.35.2. Histone Methylation 14.35.3. Histone Acetylation 14.35.4. Large Non-coding RNA 14.35.5. MicroRNA Modification 14.35.6. Chromatin Structures 14.36. ASEAN EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 14.36.1. Histone Deacetylase (HDAC) Inhibitors 14.36.2. DNA Methyltransferase (DNMT) Inhibitors 14.37. ASEAN EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 14.37.1. Oncology 14.37.2. Non-oncology 14.38. Rest of Asia Pacific EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 14.38.1. Reagents 14.38.2. Kits 14.38.3. Instruments 14.38.4. Enzymes 14.38.5. Services 14.39. Rest of Asia Pacific EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 14.39.1. DNA Methylation 14.39.2. Histone Methylation 14.39.3. Histone Acetylation 14.39.4. Large Non-coding RNA 14.39.5. MicroRNA Modification 14.39.6. Chromatin Structures 14.40. Rest of Asia Pacific EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 14.40.1. Histone Deacetylase (HDAC) Inhibitors 14.40.2. DNA Methyltransferase (DNMT) Inhibitors 14.41. Rest of Asia Pacific EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 14.41.1. Oncology 14.41.2. Non-oncology 14.42. Asia Pacific EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Attractiveness Analysis 14.42.1. By Product 14.42.2. By Technology 14.42.3. By Type of Therapy 14.42.4. By Applications 14.43. PEST Analysis 14.44. Key Trends 14.45. Key Developments 15. Middle East & Africa EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Analysis 15.1. Key Findings 15.2. Middle East & Africa EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Overview 15.3. Middle East & Africa EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Product 15.4. Middle East & Africa EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 15.4.1. Reagents 15.4.2. Kits 15.4.3. Instruments 15.4.4. Enzymes 15.4.5. Services 15.5. Middle East & Africa EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Technology 15.6. Middle East & Africa EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 15.6.1. DNA Methylation 15.6.2. Histone Methylation 15.6.3. Histone Acetylation 15.6.4. Large Non-coding RNA 15.6.5. MicroRNA Modification 15.6.6. Chromatin Structures 15.7. Middle East & Africa EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Type of Therapy 15.8. Middle East & Africa EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 15.8.1. Histone Deacetylase (HDAC) Inhibitors 15.8.2. DNA Methyltransferase (DNMT) Inhibitors 15.9. Middle East & Africa EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Applications 15.10. Middle East & Africa EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 15.10.1. Oncology 15.10.2. Non-oncology 15.11. Middle East & Africa EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Country 15.12. Middle East & Africa EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Country 15.12.1. GCC Countries 15.12.2. South Africa 15.12.3. Nigeria 15.12.4. Egypt 15.12.5. Rest of Middle East & Africa 15.13. Middle East & Africa EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Analysis, By Country 15.14. GCC Countries EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 15.14.1. Reagents 15.14.2. Kits 15.14.3. Instruments 15.14.4. Enzymes 15.14.5. Services 15.15. GCC Countries EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 15.15.1. DNA Methylation 15.15.2. Histone Methylation 15.15.3. Histone Acetylation 15.15.4. Large Non-coding RNA 15.15.5. MicroRNA Modification 15.15.6. Chromatin Structures 15.16. GCC Countries EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 15.16.1. Histone Deacetylase (HDAC) Inhibitors 15.16.2. DNA Methyltransferase (DNMT) Inhibitors 15.17. GCC Countries EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 15.17.1. Oncology 15.17.2. Non-oncology 15.18. South Africa EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 15.18.1. Reagents 15.18.2. Kits 15.18.3. Instruments 15.18.4. Enzymes 15.18.5. Services 15.19. South Africa EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 15.19.1. DNA Methylation 15.19.2. Histone Methylation 15.19.3. Histone Acetylation 15.19.4. Large Non-coding RNA 15.19.5. MicroRNA Modification 15.19.6. Chromatin Structures 15.20. South Africa EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 15.20.1. Histone Deacetylase (HDAC) Inhibitors 15.20.2. DNA Methyltransferase (DNMT) Inhibitors 15.21. South Africa EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 15.21.1. Oncology 15.21.2. Non-oncology 15.22. Nigeria EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 15.22.1. Reagents 15.22.2. Kits 15.22.3. Instruments 15.22.4. Enzymes 15.22.5. Services 15.23. Nigeria EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 15.23.1. DNA Methylation 15.23.2. Histone Methylation 15.23.3. Histone Acetylation 15.23.4. Large Non-coding RNA 15.23.5. MicroRNA Modification 15.23.6. Chromatin Structures 15.24. Nigeria EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 15.24.1. Histone Deacetylase (HDAC) Inhibitors 15.24.2. DNA Methyltransferase (DNMT) Inhibitors 15.25. Nigeria EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 15.25.1. Oncology 15.25.2. Non-oncology 15.26. Egypt EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 15.26.1. Reagents 15.26.2. Kits 15.26.3. Instruments 15.26.4. Enzymes 15.26.5. Services 15.27. Egypt EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 15.27.1. DNA Methylation 15.27.2. Histone Methylation 15.27.3. Histone Acetylation 15.27.4. Large Non-coding RNA 15.27.5. MicroRNA Modification 15.27.6. Chromatin Structures 15.28. Egypt EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 15.28.1. Histone Deacetylase (HDAC) Inhibitors 15.28.2. DNA Methyltransferase (DNMT) Inhibitors 15.29. Egypt EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 15.29.1. Oncology 15.29.2. Non-oncology 15.30. Rest of Middle East & Africa EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 15.30.1. Reagents 15.30.2. Kits 15.30.3. Instruments 15.30.4. Enzymes 15.30.5. Services 15.31. Rest of Middle East & Africa EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 15.31.1. DNA Methylation 15.31.2. Histone Methylation 15.31.3. Histone Acetylation 15.31.4. Large Non-coding RNA 15.31.5. MicroRNA Modification 15.31.6. Chromatin Structures 15.32. Rest of Middle East & Africa EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 15.32.1. Histone Deacetylase (HDAC) Inhibitors 15.32.2. DNA Methyltransferase (DNMT) Inhibitors 15.33. Rest of Middle East & Africa EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 15.33.1. Oncology 15.33.2. Non-oncology 15.34. Middle East & Africa EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Attractiveness Analysis 15.34.1. By Product 15.34.2. By Technology 15.34.3. By Type of Therapy 15.34.4. By Applications 15.35. PEST Analysis 15.36. Key Trends 15.37. Key Developments 16. South America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Analysis 16.1. Key Findings 16.2. South America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Overview 16.3. South America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Product 16.4. South America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 16.4.1. Reagents 16.4.2. Kits 16.4.3. Instruments 16.4.4. Enzymes 16.4.5. Services 16.5. South America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Technology 16.6. South America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 16.6.1. DNA Methylation 16.6.2. Histone Methylation 16.6.3. Histone Acetylation 16.6.4. Large Non-coding RNA 16.6.5. MicroRNA Modification 16.6.6. Chromatin Structures 16.7. South America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Type of Therapy 16.8. South America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 16.8.1. Histone Deacetylase (HDAC) Inhibitors 16.8.2. DNA Methyltransferase (DNMT) Inhibitors 16.9. South America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Applications 16.10. South America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 16.10.1. Oncology 16.10.2. Non-oncology 16.11. South America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Value Share Analysis, By Country 16.12. South America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Country 16.12.1. Brazil 16.12.2. Colombia 16.12.3. Argentina 16.12.4. Rest of South America 16.13. South America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Analysis, By Country 16.14. Brazil EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 16.14.1. Reagents 16.14.2. Kits 16.14.3. Instruments 16.14.4. Enzymes 16.14.5. Services 16.15. Brazil EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 16.15.1. DNA Methylation 16.15.2. Histone Methylation 16.15.3. Histone Acetylation 16.15.4. Large Non-coding RNA 16.15.5. MicroRNA Modification 16.15.6. Chromatin Structures 16.16. Brazil EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 16.16.1. Histone Deacetylase (HDAC) Inhibitors 16.16.2. DNA Methyltransferase (DNMT) Inhibitors 16.17. Brazil EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 16.17.1. Oncology 16.17.2. Non-oncology 16.18. Colombia EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 16.18.1. Reagents 16.18.2. Kits 16.18.3. Instruments 16.18.4. Enzymes 16.18.5. Services 16.19. Colombia EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 16.19.1. DNA Methylation 16.19.2. Histone Methylation 16.19.3. Histone Acetylation 16.19.4. Large Non-coding RNA 16.19.5. MicroRNA Modification 16.19.6. Chromatin Structures 16.20. Colombia EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 16.20.1. Histone Deacetylase (HDAC) Inhibitors 16.20.2. DNA Methyltransferase (DNMT) Inhibitors 16.21. Colombia EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 16.21.1. Oncology 16.21.2. Non-oncology 16.22. Argentina EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 16.22.1. Reagents 16.22.2. Kits 16.22.3. Instruments 16.22.4. Enzymes 16.22.5. Services 16.23. Argentina EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 16.23.1. DNA Methylation 16.23.2. Histone Methylation 16.23.3. Histone Acetylation 16.23.4. Large Non-coding RNA 16.23.5. MicroRNA Modification 16.23.6. Chromatin Structures 16.24. Argentina EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 16.24.1. Histone Deacetylase (HDAC) Inhibitors 16.24.2. DNA Methyltransferase (DNMT) Inhibitors 16.25. Argentina EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 16.25.1. Oncology 16.25.2. Non-oncology 16.26. Rest of South America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Product 16.26.1. Reagents 16.26.2. Kits 16.26.3. Instruments 16.26.4. Enzymes 16.26.5. Services 16.27. Rest of South America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Technology 16.27.1. DNA Methylation 16.27.2. Histone Methylation 16.27.3. Histone Acetylation 16.27.4. Large Non-coding RNA 16.27.5. MicroRNA Modification 16.27.6. Chromatin Structures 16.28. Rest of South America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Type of Therapy 16.28.1. Histone Deacetylase (HDAC) Inhibitors 16.28.2. DNA Methyltransferase (DNMT) Inhibitors 16.29. Rest of South America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Forecast, By Applications 16.29.1. Oncology 16.29.2. Non-oncology 16.30. South America EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES Market Attractiveness Analysis 16.30.1. By Product 16.30.2. By Technology 16.30.3. By Type of Therapy 16.30.4. By Applications 16.31. PEST Analysis 16.32. Key Trends 16.33. Key Developments 17. Company Profiles 17.1. Market Share Analysis, By Company 17.2. Competition Matrix 17.2.1. Competitive Benchmarking of key players By price, presence, market share, Technology, and R&D investment 17.2.2. New Product Launches and Product Enhancements 17.2.3. Market Consolidation 17.2.3.1. M&A By Regions, Investment and Technology 17.2.3.2. M&A Key Players, Forward Integration and Backward Integration 17.3. Company Profiles: Key Players 17.3.1. Acetylon Pharmaceuticals INC 17.3.1.1. Company Overview 17.3.1.2. Financial Overview 17.3.1.3. Product Portfolio 17.3.1.4. Business Strategy 17.3.1.5. Recent Developments 17.3.1.6. Development Footprint 17.3.2. Cell Centric LTD 17.3.3. Celgene Corporation 17.3.4. Epigentek Group, INC 17.3.5. Envivo Pharmaceuticals, INC 17.3.6. Oryzon Genomics 17.3.7. S.A. 17.3.8. 4SC AG 17.3.9. Celleron Therapeutics 17.3.10. Eisai Co. LTD 17.3.11. Astex Pharmaceuticals 17.3.12. Base Genomics 17.3.13. Chroma Therapeutics 17.3.14. Roche Diagnostics 17.3.15. Thermo Fisher Scientific 17.3.16. Novartis AG 17.3.17. Illumina INC 17.3.18. Qiagen 17.3.19. Abcam PLC 17.3.20. Merck KGaA 17.3.21. Others